List of articles with "Kelun-Biotech"

Sacituzumab Success

Sacituzumab Success

China Chengdu Kelun-Biotech Sacituzumab Urothelial Carcinoma
Kelun-Biotech's Lung Cancer Trial

Kelun-Biotech's Lung Cancer Trial

China Chengdu Kelun-Biotech KEYTRUDA Sac-TMT
Kelun-Biotech at CCHIO 2025

Kelun-Biotech at CCHIO 2025

China ADC Kelun-Biotech Sacituzumab Kunming
Trastuzumab Botidotin Results

Trastuzumab Botidotin Results

China Chengdu Kelun-Biotech ESMO 2025 Trastuzumab Botidotin
Sacituzumab Tirumotecan

Sacituzumab Tirumotecan

China Chengdu Kelun-Biotech sacituzumab tirumotecan ESMO
Trastuzumab Botidotin Approved

Trastuzumab Botidotin Approved

China Chengdu Kelun-Biotech Trastuzumab Botidotin HER2-Positive BC
Kelun-Biotech's Sac-TMT Approval

Kelun-Biotech's Sac-TMT Approval

China Chengdu Kelun-Biotech TROP2 ADC Sac-TMT
Kelun-Biotech at ESMO 2025

Kelun-Biotech at ESMO 2025

Germany Berlin Cancer Research Kelun-Biotech ESMO
A400/EP0031 NMPA Review

A400/EP0031 NMPA Review

China Chengdu Kelun-Biotech A400/EP0031 RET Inhibitor
Kelun-Biotech 2025 Results

Kelun-Biotech 2025 Results

China Chengdu oncology Kelun-Biotech Sacituzumab
Kelun-Biotech & Windward Bio

Kelun-Biotech & Windward Bio

China Chengdu Kelun-Biotech Windward Bio SKB378
Kelun-Biotech's SKB315 Approval

Kelun-Biotech's SKB315 Approval

China Chengdu Kelun-Biotech Tagitanlimab SKB315
Breakthrough for Sac-TMT

Breakthrough for Sac-TMT

China Chengdu Kelun-Biotech Tagitanlimab Sac-TMT
Kelun-Biotech Cancer Study

Kelun-Biotech Cancer Study

China Chengdu Kelun-Biotech TROP2 ADC sacituzumab tirumotecan
Sacituzumab Tirumotecan

Sacituzumab Tirumotecan

China Chengdu Kelun-Biotech NSCLC EGFR-Mutant
Kelun-Biotech's $250 Million Raise

Kelun-Biotech's $250 Million Raise

China healthcare Chengdu Biopharma Kelun-Biotech
Kelun-Biotech at ASCO 2025

Kelun-Biotech at ASCO 2025

USA Chicago Kelun-Biotech TROP2 ADC Sac-TMT
Kelun-Biotech's New NDA Approval

Kelun-Biotech's New NDA Approval

China Chengdu Kelun-Biotech sacituzumab-tirumotecan TROP2-ADC
Kelun-Biotech at ASCO 2025

Kelun-Biotech at ASCO 2025

China Chengdu Cancer Research Kelun-Biotech ASCO 2025
FDA Approves SKB518

FDA Approves SKB518

USA Chengdu Kelun-Biotech SKB518 ADC drug
Kelun Biotech's Breakthrough

Kelun Biotech's Breakthrough

China Chengdu Kelun-Biotech Sacituzumab TROP2 ADC
Kelun-Biotech 2024 Results

Kelun-Biotech 2024 Results

China Chengdu biotechnology Kelun-Biotech TROP2 ADC
SKB107 NMPA Approval

SKB107 NMPA Approval

China Chengdu Kelun-Biotech SKB107 Bone Metastasis
Sacituzumab Update

Sacituzumab Update

China Chengdu Kelun-Biotech Sacituzumab Lung Cancer
Kelun-Biotech at ASCO 2025

Kelun-Biotech at ASCO 2025

USA San Francisco Kelun-Biotech TROP2 ADC sacituzumab tirumotecan
Tagitanlimab Approved

Tagitanlimab Approved

China Chengdu Kelun-Biotech Tagitanlimab Nasopharyngeal-Cancer
Kelun-Biotech's New License Deal

Kelun-Biotech's New License Deal

China Chengdu Kelun-Biotech Windward Bio TSLP Antibody
Kelun-Biotech’s New TNBC Drug

Kelun-Biotech’s New TNBC Drug

China Chengdu Kelun-Biotech Sacituzumab TNBC

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.